Broughall J M, Bywater M J, Holt H A, Reeves D S
Infection. 1979;7(3):113-8. doi: 10.1007/BF01641309.
Rrine collections were made by ten volunteers taking cotrimoxazole and a sulphamoxole/trimethoprim combination on a cross-over basis. The latter was given in approximately half the dose of cotrimoxazole. Following collection of urine and its sterile filtration, the trimethoprim and sulphonamide concentrations were estimated. The urines were then inoculated with various species of Enterobacteriaceae whose minimum inhibitory concentrations had been previously determined. The viable counts in these urines were followed for 24 hours and from these the times to kill 90% of bacteria were calculated. These were very reproducible for any one experiment but showed no correlation with drug concentration, source of the urine or organism sensitivity, except for one organism which had high resistance to both sulphonamide and trimethoprim. When the organism was sensitive to at least trimethoprim a slow bactericidal effect was generally seen with either combination. We concluded that in this type of experiment the higher dosed combination showed no advantage contrary to a previous report, but in agreement with another. This brings into question the current dosage regime of cotrimoxazole when used to treat urinary tract infections in that its higher dosage over certain other sulphonamide/trimethoprim combinations appears to confer no advantage in our experiments.
十名志愿者采用交叉给药的方式,分别服用复方新诺明以及磺胺甲恶唑/甲氧苄啶组合药物来收集尿液。后者的服用剂量约为复方新诺明的一半。收集尿液并进行无菌过滤后,测定甲氧苄啶和磺胺类药物的浓度。然后将尿液接种上先前已测定最低抑菌浓度的各种肠杆菌科细菌。对这些尿液中的活菌计数跟踪24小时,并据此计算出杀灭90%细菌所需的时间。对于任何一项实验而言,这些时间都具有很好的重复性,但除了一种对磺胺类药物和甲氧苄啶均具有高抗性的细菌外,它们与药物浓度、尿液来源或微生物敏感性均无关联。当微生物至少对甲氧苄啶敏感时,通常两种组合都会呈现出缓慢的杀菌效果。我们得出的结论是,在这类实验中,与之前的一份报告相反,但与另一份报告一致,高剂量组合并未显示出优势。这就对复方新诺明目前用于治疗尿路感染的给药方案提出了质疑,因为在我们的实验中,其高于某些其他磺胺类药物/甲氧苄啶组合的剂量似乎并未带来优势。